Response:

Harper and Poole report that collagen-related peptide (CRP) caused potentiation of dense granule secretion in murine platelets deficient in Protein kinase C (PKC) θ isoform.1  They also show that pretreatment of human platelets with PKCθ isoform selective RACK peptide results in enhanced dense granule secretion upon stimulation with CRP.1  They argue that these results do not agree with our recent work2  demonstrating a positive role for PKCθ in platelet activation.

Our experiments2  were done with higher concentrations of CRP (10 and 20 μg/mL). It is evident from Figure 1 of the work by Harper and Poole1  that the potentiating effects of CRP on dense granule secretion are more apparent at lower agonist concentrations and there is no potentiation when 10 μg/mL CRP was used. Hence, we decided to perform additional experiments with lower concentrations of CRP (2 and 5 μg/mL), which were not used in our previous study.2  The lower concentrations of CRP (2 μg/mL) caused a potentiating effect on dense granule secretion from PKCθ−/− platelets (0.320 ± 0.0064 nmoles/3.7 × 108 platelets; P < .05), compared with wild-type (WT) littermates (0.238 ± 0.004 nmoles/3.7 × 108 platelets). Slightly higher concentrations (5 μg/mL) showed no significant differences (0.685 ± 0.044 vs 0.512 ± 0.044 nmoles/3.7 × 108 platelets; P > .1). Hence, we agree with Harper and Poole1  that very low concentrations of CRP cause potentiation of dense granule release in platelets lacking functional PKCθ.

Harper and Poole1  claimed that they reported that CRP-induced secretion is enhanced in their previous study.3  In their previous study3  they actually stated that “Interestingly, however, no difference in adenosine triphosphate (ATP) secretion was seen between PKCθ−/− and WT platelets in response to CRP (Figure 3B) or collagen (Figure 3C).1  It is not clear to us how, using the same concentrations of CRP used in their previous study (1 and 5 μg/mL),3  they could demonstrate significant potentiation in PKCθ null mouse platelets (P < .001) in Figure 1A of their study.1  Hence their current results1  are in conflict with their own previous work.3  It is also important to note that in their previous study,3  the ATP release numbers were nearly 10-fold higher than in the current work (Figure 1A1 ).

Consistent with our study,2  Cohen et al4  recently reported that PKCθ plays a positive regulatory role in platelet activation and secretion. Consistent with our in vivo thrombosis results,2  they noticed that the bleeding times were increased in PKCθ−/− mice.4 

Harper and Poole1  argue that phosphorylated syntaxin 4 would dissociate from SNAP23 and thereby reduce secretion, thus syntaxin 4 phosphorylation would negatively regulate release. Previous studies5,6  reported dissociation of syntaxin 4 and SNAP23 upon platelet activation though no time course for this process was given. Dissociation could occur after fusion, during which the components of the SNARE complex might be recycled, though it is not clear whether this is significant in an activated platelet. The evidence that panPKC inhibitors abolish phosphorylation of syntaxin as well as secretion is indicative that syntaxin phosphorylation could be important for secretion.5 

In conclusion, we emphasize that our data2  are supported by a recent independent study4  that confirms a positive regulatory role for PKCθ in platelets.

Acknowledgments: We thank Ms Monica Dupon for her help in breeding and genotyping the knockout mice.

This work was supported by research grants HL60683 and HL93231 from the National Institutes of Health.

Approval was obtained from Temple University institutional review board for the studies. Informed consent was provided in accordance with the declaration of Helsinki.

Contribution: S.P.K. wrote the response and provided overall supervision and interpretation of the data; and J.J. performed the experiments.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Satya P. Kunapuli, PhD, Department of Physiology, Temple University Medical School, Philadelphia PA 19140; e-mail: [email protected].

1
Harper
 
MT
Poole
 
AW
PKCtheta in platelet activaiton.
Blood
2009
, vol. 
114
  
0
2
Nagy
 
B
Bhavaraju
 
K
Getz
 
T
Bynagari
 
YS
Kim
 
S
Kunapuli
 
SP
Impaired activation of platelets lacking protein kinase C-theta isoform.
Blood
2009
, vol. 
113
 (pg. 
2557
-
2567
)
3
Hall
 
KJ
Harper
 
MT
Gilio
 
K
Cosemans
 
JM
Heemskerk
 
JW
Poole
 
AW
Genetic analysis of the role of protein kinase Ctheta in platelet function and thrombus formation.
PLoS ONE
2008
, vol. 
3
 pg. 
e3277
 
4
Cohen
 
S
Braiman
 
A
Shubinsky
 
G
Ohayon
 
A
Altman
 
A
Isakov
 
N
PKCtheta is required for hemostasis and positive regulation of thrombin-induced platelet aggregation and alpha-granule secretion.
Biochem Biophys Res Commun
2009
5
Chung
 
SH
Polgar
 
J
Reed
 
GL
Protein kinase C phosphorylation of syntaxin 4 in thrombin-activated human platelets.
J Biol Chem
2000
, vol. 
275
 (pg. 
25286
-
25291
)
6
Flaumenhaft
 
R
Croce
 
K
Chen
 
E
Furie
 
B
Furie
 
BC
Proteins of the exocytotic core complex mediate platelet alpha-granule secretion. Roles of vesicle-associated membrane protein, SNAP-23, and syntaxin 4.
J Biol Chem
1999
, vol. 
274
 (pg. 
2492
-
2501
)

National Institutes of Health

Sign in via your Institution